BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33929528)

  • 61. Impact of the more restrictive definition of atypical squamous cells introduced by the 2001 Bethesda System on the sensitivity and specificity of the Papanicolaou test: a 5-year follow-up study of Papanicolaou tests originally interpreted as ASCUS, reclassified according to Bethesda 2001 criteria.
    Thrall MJ; Pambuccian SE; Stelow EB; McKeon DM; Miller L; Savik K; Gulbahce HE
    Cancer; 2008 Jun; 114(3):171-9. PubMed ID: 18454461
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cervical Cancer Screening: Comparison of Conventional Pap Smear Test, Liquid-Based Cytology, and Human Papillomavirus Testing as Stand-alone or Cotesting Strategies.
    Liang LA; Einzmann T; Franzen A; Schwarzer K; Schauberger G; Schriefer D; Radde K; Zeissig SR; Ikenberg H; Meijer CJLM; Kirkpatrick CJ; Kölbl H; Blettner M; Klug SJ
    Cancer Epidemiol Biomarkers Prev; 2021 Mar; 30(3):474-484. PubMed ID: 33187968
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A comparison of high-risk human papillomavirus DNA detection between urine and cervical sample testing in women with abnormal Pap smears.
    Punyashthira A; Horthongkham N; Jaishuen A; Jareemit N; Achariyapota V
    J Obstet Gynaecol Res; 2022 Feb; 48(2):448-455. PubMed ID: 34750932
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluation of Anal Cytology in Women with History of Abnormal Pap Smear, Cervical Intraepithelial Neoplasia, Cervical Cancer and High Risk HPV for Anogenital Dysplasia.
    Hosseini MS; Khosravi D; Farzaneh F; Ebrahimi A; Arab M; Ashraf Ganjoie T; Jamdar F; Moridi A; Chehrazi M
    Asian Pac J Cancer Prev; 2018 Nov; 19(11):3071-3075. PubMed ID: 30485943
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Distribution of human papillomavirus types, cervical cancer screening history, and risk factors for infection in Manitoba.
    Demers AA; Shearer B; Severini A; Lotocki R; Kliewer EV; Stopera S; Wong T; Jayaraman G
    Chronic Dis Inj Can; 2012 Sep; 32(4):177-85. PubMed ID: 23046799
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
    Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
    Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Reducing overtreatment associated with overdiagnosis in cervical cancer screening-A model-based benefit-harm analysis for Austria.
    Sroczynski G; Esteban E; Widschwendter A; Oberaigner W; Borena W; von Laer D; Hackl M; Endel G; Siebert U
    Int J Cancer; 2020 Aug; 147(4):1131-1142. PubMed ID: 31872420
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Longitudinal cytological follow-up of patients with a papanicolaou test interpretation of "atypical squamous cells of undetermined significance" that was followed by a negative reflex test for high-risk human papillomavirus types.
    Rodriguez R; Fadare O
    Int J Gynecol Pathol; 2008 Jan; 27(1):108-12. PubMed ID: 18156984
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear.
    Molden T; Nygård JF; Kraus I; Karlsen F; Nygård M; Skare GB; Skomedal H; Thoresen SO; Hagmar B
    Int J Cancer; 2005 May; 114(6):973-6. PubMed ID: 15645423
    [TBL] [Abstract][Full Text] [Related]  

  • 70. An online survey on emotions, impact on everyday life, and educational needs of women with HPV positivity or abnormal Pap smear result.
    Ciavattini A; Delli Carpini G; Giannella L; Del Fabro A; Banerji V; Hall G; Barbero M; Sopracordevole F
    Medicine (Baltimore); 2021 Nov; 100(45):e27177. PubMed ID: 34766557
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of cytopathologic findings in patients with negative Pap test and positive high-risk HPV infection among three groups.
    Kasraei S; Ghahghaei-Nezamabadi A; Seifollahi A; Aghajani F; Nakhostin-Ansari A; Zarei N; Tehranian A
    Arch Gynecol Obstet; 2022 Sep; 306(3):857-863. PubMed ID: 35233666
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
    Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
    Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China's largest CAP-certified laboratory.
    Zheng B; Li Z; Griffith CC; Yan S; Chen C; Ding X; Liang X; Yang H; Zhao C
    Cancer Cytopathol; 2015 Jul; 123(7):428-34. PubMed ID: 25954852
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
    Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
    BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Quality control for normal liquid-based cytology: rescreening, high-risk HPV targeted reviewing and/or high-risk HPV detection?
    Depuydt CE; Arbyn M; Benoy IH; Vandepitte J; Vereecken AJ; Bogers JJ
    J Cell Mol Med; 2009 Sep; 13(9B):4051-60. PubMed ID: 18544049
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?
    Bhatla N; Dar L; Patro AR; Kumar P; Kriplani A; Gulati A; Iyer VK; Mathur SR; Sreenivas V; Shah KV; Gravitt PE
    Cancer Epidemiol; 2009 Dec; 33(6):446-50. PubMed ID: 19931499
    [TBL] [Abstract][Full Text] [Related]  

  • 77. HPV testing with cytology triage for cervical cancer screening in routine practice.
    Louvanto K; Chevarie-Davis M; Ramanakumar AV; Franco EL; Ferenczy A
    Am J Obstet Gynecol; 2014 May; 210(5):474.e1-7. PubMed ID: 24373948
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women-A cohort study.
    Westre B; Giske A; Guttormsen H; Wergeland Sørbye S; Skjeldestad FE
    PLoS One; 2019; 14(11):e0221546. PubMed ID: 31689301
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.
    Tiews S; Steinberg W; Schneider W; Hanrath C
    J Clin Virol; 2009 Nov; 46 Suppl 3():S11-5. PubMed ID: 20129068
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Glandular Lesions of the Cervix in Clinical Practice: A Cytology, Histology, and Human Papillomavirus Correlation Study From 2 Institutions.
    Miller RA; Mody DR; Tams KC; Thrall MJ
    Arch Pathol Lab Med; 2015 Nov; 139(11):1431-6. PubMed ID: 25951104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.